## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.4% below STRENGTH zone (4.0-10.0%); PEG 35.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 10)

**1. Lowey Dannenberg Notifies Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $250,000 in Losses to Contact the Firm**
- Source: GlobeNewswire | 20251205T173229 | Bearish | Relevance: 100%
- Lowey Dannenberg P.C. has filed a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who purchased securities between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter made false statements regarding defects in its Novum LVP product, which caused patient harm and financial losses for investors. Investors with losses exceeding $250,000 are encouraged to contact the firm.

**2. BAX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit**
- Source: yourerie.com | 20251205T171004 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Baxter International, Inc. for alleged federal securities law violations. The lawsuit claims Baxter misled investors by failing to disclose systemic defects in its Novum LVP medical devices, which caused widespread malfunctions and risks of serious injury or death to patients. Investors who purchased Baxter securities between February 23, 2022, and October 29, 2025, are encouraged to join the lawsuit and have until December 15, 2025, to request to be appointed as lead plaintiff.

**3. Lowey Dannenberg Notifies Baxter International, Inc.**
- Source: GlobeNewswire | 20251205T123000 | Bearish | Relevance: 100%
- Lowey Dannenberg P.C. has filed a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who purchased securities between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter made false and misleading statements about the safety and efficacy of its Novum LVP product, which suffered from systemic defects causing widespread malfunctions. Investors who suffered losses exceeding $250,000 are encouraged to contact the firm, with a deadline of December 15, 2025, to serve as Lead Plaintiff.

**4. BAX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!**
- Source: CNYhomepage.com | 20251205T120744 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who purchased securities between February 23, 2022, and October 29, 2025. The lawsuit alleges that Baxter misled investors regarding systemic defects in its Novum LVP medical devices, which caused widespread malfunctions and posed serious risks to patients. Investors have until December 15, 2025, to request to be appointed as lead plaintiff in the case.

**5. Pomerantz LLP Notifies Investors of Class Action Filing Against Baxter International, Inc. – BAX**
- Source: Fox 59 | 20251205T070000 | Bearish | Relevance: 100%
- Pomerantz LLP has announced the filing of a class action lawsuit against Baxter International, Inc. (NYSE: BAX) concerning alleged securities fraud or unlawful business practices. Investors who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff. The lawsuit follows a significant drop in Baxter's stock price after the company announced a voluntary and temporary pause on shipments of its Novum LVP medical device.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.17M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.4x requires aggressive growth execution.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Long-term trend broken: trading 31.3% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.42 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.42 |
| Forward P/E | 8.0 |
| Current P/E | 7.8 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.5% to -1.4% (-4.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.69x), long-term trend not supportive. RSI neutral at 43. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.36% (CS: 42) | Neutral |
| RSI_14 | 43.2 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.904x | Below |
| vs SMA200 | 0.687x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.54
- **Stop Loss:** $17.38 (6.3% risk)
- **Target:** $19.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 431
- **Position Value:** $7,990.74
- **Portfolio %:** 7.99%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*